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Abstract
Background: Co-occurring mental health and substance use disorders (COD) are the norm
rather than the exception. It is therefore critical that performance measures are developed to
assess the quality of care for individuals with COD irrespective of whether they seek care in mental
health systems or substance abuse systems or both.
Methods: We convened an expert panel and asked them to rate a series of structure, process,
and outcomes measures for COD using a structured evaluation tool with domains for importance,
usefulness, validity, and practicality.
Results: We chose twelve measures that demonstrated promise for future pilot testing and
refinement. The criteria that we applied to select these measures included: balance across
structure, process, and outcome measures, quantitative ratings from the panelists, narrative
comments from the panelists, and evidence the measure had been tested in a similar form
elsewhere.
Conclusion: To be successful performance measures need to be developed in such a way that they
align with needs of administrators and providers. Policymakers need to work with all stakeholders
to establish a concrete agenda for developing, piloting and implementing performance measures
that include COD. Future research could begin to consider strategies that increase our ability to
use administrative coding in mental health and substance use disorder systems to efficiently capture
quality relevant clinical data.
Background
There has been a dramatic growth in recent years in the
development of performance measures to monitor and
evaluate the quality of medical care [1]. Examples include
performance measures developed for the Institute of Med-
icine's (IOMs) national report card [2], the National Com-
mittee for Quality Assurance's (NCQA) Healthcare
Effectiveness Data and Information Set (HEDIS) [3], the
National Quality Forum's (NQF) "Standardizing Ambula-
tory Care Performance Measures" project [4], and the
American Medical Association's outpatient chronic care
clinical performance measures [5].
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These measures have been used for everything from inter-
nal auditing and quality improvement efforts to bench-
marking performance against national averages. Most
recently, performance measures are being used to finan-
cially reward performance with pay-for-performance initi-
atives and to distinguish between high and low
performing health care systems [6-8]. The substance abuse
and mental health fields have long used performance
measures such as length of stay, readmission rates, and
abstinence during drug treatment. Despite this, the
growth of performance measure development in these
fields has not kept pace with some other sectors of medi-
cine [9,10]. As with other fields, this interest has been
motivated by calls to increase transparency and accounta-
bility and thereby improve the overall quality of services
delivered [11-13].
The limited numbers of performance measures available
tend to focus on either mental health disorders (MHD)
[14,15] or substance use disorders (SUD) [16,17], despite
the fact that these disorders have a high probability of co-
occurrence. This reflects the segmentation of mental
health and substance abuse services into distinct clinical
and organizational "silos" [18].
The idea of developing performance measures for co-
occurring conditions that cut across these silos is still in its
infancy [19]. A notable effort by researchers to develop
such measures is the Substance Abuse and Mental Health
Services Administration's (SAMHSA) National Outcome
Measures (NOMs) project [20]. NOMs comprise ten out-
come domains conceptualized to apply to a variety of
populations, including persons with COD. Operationalz-
ing NOMs into concrete, measurable performance indica-
tors, however, is still necessary.
SAMSHA contracted with the RAND Corporation in 2006-
2007 to begin to conceptualize and develop performance
measures for COD. This pilot effort was focused on COD
performance measures specifically for SUD settings. How-
ever, we discuss how these measures can be easily adapted
to be used in MHD settings. The project was designed to
rely on the advice of an expert panel to aid in the assess-
ment of a set of candidate COD performance measures.
Our goal was to develop a small number of measures that
could serve as examples of the types of measures for COD
that could be pilot tested and refined for future use. Here
we outline the process we used to develop these measures
and describe the final set of measures that were devel-
oped.
Methods
We convened an expert panel that included a range of
stakeholders. Our goal was to include the diverse perspec-
tives of different groups involved in performance meas-
urement in substance abuse and mental health. To this
end, we first identified three broad perspectives to include
on the panel: (1) state and local perspectives (e.g., individ-
uals with leadership roles related to performance meas-
urement at state and local substance abuse and mental
health agencies and national substance abuse and mental
health professional associations); (2) health plan perspec-
tives (e.g., individuals who have a role in performance
measurement at behavioral health plans); and (3) aca-
demic perspectives (e.g., experts from leading academic
and research centers who have published on this topic).
We identified a convenience sample of more than thirty
experts with backgrounds in at least one of these perspec-
tives and asked them to participate in our panel. Of those
contacted, 18 agreed to participate. There was an even dis-
tribution of panelists from these perspectives. Based on
their career experience, some panelists were able to con-
sider the measures from multiple perspectives. Panelists
were asked to respond to a series of quarterly question-
naires over the course of one year. The first two question-
naires asked participants to evaluate the general
framework we developed. The remaining questionnaires
asked participants to evaluate a three sets of performance
measures (structure, process, and outcome) using a sys-
tematic data collection form described below. A majority
of panelists responded to each questionnaire.
At the start of the project, we asked the panelists to evalu-
ate the basic framework we established to conceptualize,
develop, and evaluate our performance measures. The pri-
mary conceptual backdrop for the development of the
measures was Donabedian's classic triad of structures,
processes, and outcomes [21]. We proposed using this
framework to categorize our measures.
On the advice of the panelists, we modified this approach
by creating subcategories for each part of the triad: (1)
structure (e.g., clinician characteristics, clinical informa-
tion systems, service linkages and financial); (2) process
(e.g., detection/identification, assessment, treatment, and
service integration/coordination of care) and (3) out-
comes (e.g., reduced morbidity, crime and criminal jus-
tice, stability in housing, social connectedness, and
perception of care).
The subcategories for the structure and process measures
were developed from the integration of information
derived from the literature, suggestions from the panelists,
and suggestions we received during a presentation on this
topic at a professional meeting [22]. To ensure consist-
ency with ongoing SAMHSA work in this area, the sub-
categories for the outcomes measures were derived from
the NOMs project.
In developing the performance measures we considered
existing work in this area including: (1) performance indi-Substance Abuse Treatment, Prevention, and Policy 2009, 4:18 http://www.substanceabusepolicy.com/content/4/1/18
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cators being developed for the Performance Partnership
Grants-PPG [23]; (2) local evaluations of individual Co-
Occurring State Incentive Grant (COSIG) projects [24];
(3) quality indicators for substance abuse services devel-
oped by the Washington Circle (WC) Group [25]; (4)
agency for Healthcare Research and Quality (AHRQ)
quality measure clearinghouse [26]; (5) mental health
quality indicators developed for the Healthcare Effective-
ness Data and Information Set (HEDIS) [3]; and (6) qual-
ity indicators identified and/or developed by the Center
for Quality Assessment and Improvement in Mental
Health (CQAIMH) [27].
Our goal was to develop measures that built on existing
work. We started with the assumption that existing per-
formance measures in the substance abuse and mental
health fields could be modified to apply to COD. Despite
this, we did not want to be constrained to what has
already been done. Therefore in addition to adapting
existing performance measures to COD, we also devel-
oped novel measures that we considered to be of poten-
tially high value.
The candidate measures are meant to serve as exemplars of
the types of measures that can be developed. Therefore,
some candidate measures specify a particular setting (e.g.,
inpatient) when they could potentially apply to more
than one setting depending on the circumstance. In addi-
tion, despite the fact that the measures developed were
designed to apply to substance abuse settings, they could
easily be adapted to apply to mental health settings.
We asked the panelists to provide feedback on the frame-
work we established for evaluating the measures them-
selves. We adapted the initial performance measure
evaluation tool from one developed by Hermann and col-
leagues which was provided to the first author electroni-
cally (see [27] for more information on Hermann's work).
The tool was a simple rating form divided along 6
domains ranging from clinical importance to strategic
importance. All of the ratings consisted of 5 point Likert
scales. The descriptions of the domains paralleled NCQAs
list of desirable attributes for HEDIS measures [3].
We adapted this tool by limiting it to five domains and
adapting the descriptions of these domains to apply to
COD. We asked the panelists to evaluate our choice of
domains and our descriptions of them, and they provided
us with feedback on how to improve them. Below we list
the final set of domains that we developed based on the
feedback from our panelists:
• Importance - Does the measure represent a signifi-
cant part of the overall quality picture? Does the meas-
ure represent an aspect of COD care that is meaningful
(e.g., does what is being measured represent a signifi-
cant quality deficit)?
￿ Usefulness - Will the use of the measure be helpful in
leading to strategies that will result in improvements
in patient care? Is the measure likely to have a signifi-
cant impact on patient care and have the ability to lead
to real change in patient outcomes (e.g., is the deficit
potentially correctable by an identifiable group)?
￿ Validity or Scientific Soundness - Is the measure evi-
dence based, is it sensitive to case mix or can it be
adjusted to case mix? Can it be gamed or manipu-
lated? Is the measure something that can quantita-
tively demonstrate changes over time (e.g., if the
process is corrected, would the measure be sensitive to
detecting this change)?
￿ Practicality or Feasibility - How practical is it to col-
lect information for the measure (e.g., will data collec-
tion require significant costs or be overly burdensome
with existing data systems)?
￿ Overall  - What is your overall impression of this
measure? Should this measure be included in the core
measure set?
When rating the measures, panelists were given detailed
descriptions of each measure and asked to rate the meas-
ures on each of the domains listed above using a Likert
scale where 1 represented strongly agree, 3 represented
uncertain, and 5 represented strongly disagree. Space was
also provided for panelists to provide narrative comments
on each of the measures or to propose additional meas-
ures. We also encouraged the panelists to use the space for
narrative comments to consider the most appropriate
audience for each of the proposed measures. In our initial
questionnaire to the panelists we provided several poten-
tial examples including: purchasers (public and private),
health Plans, agencies/provider organizations, individual
providers, consumers, and policymakers.
We developed a total of 36 performance measures broken
into structures, processes, and outcomes with at least one
measure for each subcategory identified above. We chose
a total of twelve measures (four from each category--struc-
ture, process, and outcome) that appeared to have the
most promise to pilot test. The criteria that we applied to
choose the set of twelve measures included: balance across
structure, process, and outcome measures, quantitative
ratings from the panelists, narrative comments from the
panelists, and evidence the measure had been tested in a
similar form elsewhere.Substance Abuse Treatment, Prevention, and Policy 2009, 4:18 http://www.substanceabusepolicy.com/content/4/1/18
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Results
Structure measures
Structure measures tell us whether or not a health care
agency or organization has the capacity for process or out-
comes measurement (e.g., infrastructure in place that ena-
bles quality measurement to occur) and in the case of
COD whether or not any integrated or linked services are
offered. To measure the quality of COD care, an agency
must first have the capacity to deliver integrated or linked
services. Structural measures are designed to enable us to
access these capacities. Table 1 presents our final refined
set of structure measures [see Additional file 1].
Measure 1 assesses the proportion of SUD providers in a
SUD specialty care setting who are trained to provide spec-
ified mental health care, and who have a certificate,
license or some other documentation to demonstrate pro-
ficiency. Data for this measure could be collected with a
facility survey. A similar measure could be created for
MHD providers by assessing the proportion of MHD pro-
viders in MHD specialty care settings who have docu-
mented proficiency in SUD care.
Measure 2 assesses the proportion of programs in a
defined service area (e.g., county, city or state) that report
having integrated services (e.g., SUD and MHD services in
the same treatment program) or co-located services (e.g.,
SUD and MHD services in the same location). Program
records used to develop this measure could be augmented
by the use of standardized instrument measures of fidelity
to the integrated services program--see [28] for an exam-
ple.
Measure 3 assesses the proportion of SUD providers in a
defined service area (e.g., county, city or state) reporting
the ability to bill for MHD services provided to patients. A
similar measure could also be developed for MHD provid-
ers providing SUD services where there are also challenges
related to billing for COD services.
Measure 4 assesses the proportion of SUD specialty care
settings in a defined service area (e.g., county, city or state)
that have formal documented referral policies for MHD
services. Data for this measure could be collected by a
facility survey that could be auditable by facility records.
Measures 1-4 have the potential to be useful for state and
local SUD and MHD administrators evaluating the level
of integration or the quality of the linkages between SUD
and MHD agencies in their jurisdiction.
Process measures
After we have determined that an agency is capable of
measuring performance and that it has some infrastruc-
ture in place to deliver integrated or linked services for
COD, a logical next step is to consider process measures
that examine how care is being delivered. Process meas-
ures are a critical link in the chain between structure meas-
ures and outcome measures because they enable us to
determine whether or not care is being delivered using evi-
dence based standards and guidelines. Without knowing
this, it isn't possible to know whether poor outcomes are
the result of inadequate program implementation, poor
program fidelity, or other factors. Table 2 presents our
final refined set of process measures [see Additional file
2].
Measure 5 assesses the proportion of individuals formally
screened for a MHD upon admission to a SUD specialty
care setting. This measure lends itself to be initially
piloted in an inpatient setting where standardized charts
are more likely. Collecting data for the measure may
require the addition of a field to initial patient intake
forms. Importantly, the data collected for this measure
could be used for denominator data for other measures.
Measure 6 assesses the proportion of individuals that
screened positive for COD in a SUD specialty care setting
that received a MHD service (or at least one integrated
service) within 30 days of screening. This measure is
adapted from measures developed by the Washington Cir-
cle Group for substance abuse settings [16] which were
pilot tested in six states by state and local substance abuse
and/or mental health agencies [17]. The pilot test revealed
that state agencies could calculate these types of measures
with routinely collected data. A measure such as this
might be useful for state-level SUD agencies and might
encourage them to develop the structural capacity to
measure COD screening.
Measure 7 assesses the proportion of COD with an inpa-
tient or day/night episode (SUD or MHD related) visit
that have at least one SUD and one MHD outpatient clinic
visit (or one integrated treatment visit) within thirty days
of discharge. This measure was adapted from a HEDIS
measure for mental illness [29]. The original HEDIS meas-
ure was found to be moderately correlated with some but
not all similar measures of outpatient performance [30].
Data collection for this measure may require chart reviews
in some systems. The denominator data could come from
the total number of positive screens found with Measure
5 above.
Measure 8 assesses the proportion of individuals with
COD that were assessed for housing stability. A measure
such as this could be transitioned into an administrative
dataset. The method of identification, however, needs to
specify whether it is based on positive screens or based on
receipt of both types of services or integrated services. Ulti-
mately it may be possible to develop specific administra-
tive codes to integrate this type of information into
administrative datasets.Substance Abuse Treatment, Prevention, and Policy 2009, 4:18 http://www.substanceabusepolicy.com/content/4/1/18
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Measures 5-8 have the potential to be useful to specialty
plan administrators to assess the level of integrated or
linked services being offered in their plan.
Outcome measures
Outcomes are the final piece of the performance measure-
ment strategy. Determining what outcomes to measure,
however, is not always easy. Different outcomes are
important to different stakeholders. For example, patients
may be most interested in outcomes that deal with
improvements to their quality of life or that improve their
functionality while policymakers may be interested in
outcomes that reduce crime or inpatient costs. Table 3
presents our final refined set of outcomes measures [see
Additional file 3]. All of these measures were based on
generic outcomes measures included in NOMs.
Measure 9 assesses the proportion of individuals with any
MHD discharged from an inpatient or residential SUD
specialty care setting with abstinence from drugs and/or
alcohol one year after discharge. The data for this measure
could come from patient report and/or laboratory tests.
This measure focuses on inpatient care; however, it is pos-
sible for a similar measure to be developed for outpatient
care.
Measure 10 assesses the proportion of individuals with
any MHD diagnosis discharged from an inpatient or resi-
dential SUD specialty setting that move from being unem-
ployed to being employed either part-time or full-time
one year after discharge. The data from this measure could
come from patient report and/or employment records. As
with Measure 9, a similar measure could be developed for
outpatient settings.
Measure 11 assesses the proportion of individuals with
any MHD diagnosis discharged from an inpatient or resi-
dential SUD specialty care setting who report having an
episode of incarceration within 6 months of discharge.
Data for this measure could come from patient report
and/or criminal justice system data. As with Measures 9-
10, a similar measure for outpatient settings could also be
developed.
Measure 12 assesses the proportion of individuals receiv-
ing care in a SUD specialty care setting with any MHD
diagnosis who report improved satisfaction with their care
as measured by a standardized instrument after 6 months
of treatment. Data for this measure could come from sat-
isfaction measures included on patient surveys. The
respondent pool for these surveys could be determined by
claims data or a checkbox for self-report of a MHD.
Measures 9-12 have the potential to be useful to SUD and
MHD providers to assess how well they are providing inte-
grated or linked SUD and MHD services.
Discussion
Developing reliable and valid performance measures for
COD that are of high value while remaining feasible to
implement is a significant challenge. This project sought
to take a step forward in the development of such meas-
ures by developing a framework to conceptualize these
measures and by considering a small set of measures for
substance abuse settings evaluated through expert consen-
sus. The model introduced by this project for initially
developing performance measures for COD is a logical
first step and could be expanded and replicated elsewhere.
Because of the qualitative nature of our analysis, we do
not present the raw data from our analysis of the expert
panelist feedback. This feedback was provided in the form
of ratings using Likert scales in combination with written
qualitative feedback for each measure. It is important to
note, however, that overall our panelists rated outcomes
measures as more important than structure and process
measures. This likely reflects the general belief that out-
comes are the ultimate aspect of quality that we are trying
to assess in any performance measurement system.
Despite this, in choosing our final set of measures, we pur-
posely included an equal number of structure, process,
and outcomes. We agree with the importance of outcomes
measures; however, we argue that these measures need to
be part of an integrated package of measures with the
intent for full implementation over time. To interpret out-
comes and to use outcomes to improve service, measures
of structure and process are essential.
A tension in performance measurement is the extent to
which measures can be developed using existing adminis-
trative data systems versus those that require additional
data collection. Using administrative data is less costly
and involves less effort; however, these measures tend to
be "black box" measures that don't really allow us to
directly assess what we want to measure. Developing new
data systems or additional data collection applets in old
data systems can be costly and if done without proper
foresight can yield limited benefits. It can be argued, how-
ever, that without considering new or modified data sys-
tems that we will never be able to measure quality
adequately.
For many psychosocial problems (e.g., homelessness,
unemployment, family interventions, legal problems),
without having a simple and efficient way of identifying
them (i.e., identifying who needs help) it is difficult to
develop performance measures that do not require exten-
sive chart reviews. This is less of a problem with develop-
ing performance measures so much as it is a problem with
making the data collection for these measures feasible. A
coding system to capture this information that could be
integrated into the clinical record is one way to solve this
problem [31].Substance Abuse Treatment, Prevention, and Policy 2009, 4:18 http://www.substanceabusepolicy.com/content/4/1/18
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This project has several limitations. In choosing the meas-
ures, we tried to achieve a balance between attributes with
a particular emphasis on practicality. There are many
other measures that could be developed. The measures
presented here are intended to serve as exemplars of the
types of measures that could be developed. They also serve
as measures that are potentially promising to pilot test.
The setting in which each measure is most applicable var-
ies (e.g., health plans, SUD organizations, providers). Our
emphasis was to focus on settings that were most likely to
have data. That data for some of these measures could
become unstable for smaller organizations. Nonetheless
the measure sets a clear goal and can aid even these small
organizations in moving towards that goal.
Several of the measures that we developed focused on
inpatient care settings. This emphasis is not meant to sug-
gest that outpatient care is not important. More outpatient
measures will need to be developed over time. Inpatient
measures; however, provide us with an environment
where we have the most control and provide us with a
date to start counting. In addition, appropriate follow-up
after inpatient care is a high priority.
These measures and others that may be developed in the
future will need to be continually refined as we gain an
understanding of their psychometric and statistical prop-
erties. Refinements will need to include weighting proce-
dures and other statistical adjustments. For example,
Measure 3 assesses the proportion of SUD providers
within a geographical area that are able to bill for MHD
services. Compared to community based SUD providers,
hospital based SUD providers may be more likely to be
able to bill for MHD services while at the same less likely
to see as many clients. Thus areas with higher proportions
of hospital based providers compared to community
based providers could score higher on this measure while
treating fewer COD clients than areas with the reverse.
Strategies to appropriately adjust for caseload will be
needed to solve these types of problems.
This project raises several avenues for future research in
this area. A logical next step is to pilot test these measures
(or other measures that are developed) in real settings.
These pilot tests could take on one of two forms: pilot tests
of measures that lend themselves to existing administra-
tive datasets versus pilot tests of measures that require
additional data collection. Existing administrative data-
sets of one or more health care organizations can used to
test the feasibility of the current specifications of the
measures. Modifications can be made to these specifica-
tions based on what is learned. It may turn out that some
of the measures that initially seemed feasible with admin-
istrative data are less amenable to this format than origi-
nally thought. Measures that involve data not contained
in administrative or claims datasets will require addi-
tional data collection. These measures can be pilot tested
in practice care settings through surveys of patients, pro-
viders, and family members.
Conclusion
Having clear processes for developing, vetting and pilot-
ing performance measures affords us an opportunity to
think about what we want to measure and contrast that
with what we are able to measure with existing data sys-
tems and infrastructure. Policymakers have a vast array of
considerations to take into account when choosing per-
formance measures. They must consider the implementa-
tion of new performance measures against the backdrop
of scarce resources and competing priorities. New per-
formance measures are critical but may not be possible
without additional resources. It is important that as this
process moves forward that all stakeholders in the field
have an opportunity to review and comment on new per-
formance measures being considered. To be successful
performance measures need to be developed in such a
way that they align with needs of administrators and pro-
viders. Policymakers need to work with all stakeholders to
establish a concrete agenda for developing, piloting and
implementing performance measures that include COD.
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